Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Atara Biotherapeutics Inc ATRA

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel... see more

NDAQ:ATRA - Post Discussion

Atara Biotherapeutics Inc > ATRA.....recent RS climbing "The Wall"
View:
Post by Iseneschal on Jul 16, 2024 10:08am

ATRA.....recent RS climbing "The Wall"

could be "A close shave"

currently at $12....a break of previous high would be meaningful....$12.46
Comment by Iseneschal on Jul 16, 2024 10:58am
LoL......FOMO's entering the fray N.H.O.D  & H.O.D post RS No selling til over $25
Comment by Iseneschal on Jul 17, 2024 9:15am
Wortha repeat....Hell ya !!!!! $14 HOLLA !!!!! On a NR this a.m!!!! Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel(TM)) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease 2024-07-17 06:00 ET - News Release Prescription Drug User Fee Act (PDUFA) Target Action ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities